We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
Read MoreHide Full Article
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare, received Priority Review designation from the FDA for the new drug application for its long-acting, injectable two-drug HIV regimen
Glaxo had filed the NDA in April seeking approval for the two-drug monthly regimen of its candidate cabotegravir and J&J’s (JNJ - Free Report) Edurant (rilpivirine) for the treatment of HIV-1-infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine.With the FDA granting a Priority Review in June, a decision is expected on Dec 29, 2019.
Meanwhile, ViiV Healthcare also announced the start of the first-ever study — CUSTOMIZE — to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in the real world. This approach can be different and an improvement from the controlled setting of a clinical study
ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer (PFE - Free Report) .
So far this year, Glaxo’s shares have outperformed the industry, rising 6% compared with the industry’s 2.6% increase.
HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, Tivicay, Triumeqand Juluca in its portfolio. In April, ViiV Healthcare gained FDA approval for a single-tablet two-drug regimen, Dovato for treatment naïve HIV- 1 adults. HIV sales totaled £1.12 billion in the first quarter of 2019 with dolutegravir-based regimens generating £1.07 million, which partly offset lower sales of established HIV products. However, on the call, the company specified that growth in the dolutegravir franchise was slower than past quarters due to a more competitive environment.
ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralizing antibodies). Other than the long-acting, injectable two-drug regimen of cabotegravir and rilpivirine, Glaxo has fostemsavir in its HIV pipeline, which has been developed to treat heavily pre-treated HIV patients. An NDA for fostemsavir is expectedto be filedin second-half 2019.
Other key players in the HIV market are Gilead (GILD - Free Report) , Merck, AbbVie and J&J.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare, received Priority Review designation from the FDA for the new drug application for its long-acting, injectable two-drug HIV regimen
Glaxo had filed the NDA in April seeking approval for the two-drug monthly regimen of its candidate cabotegravir and J&J’s (JNJ - Free Report) Edurant (rilpivirine) for the treatment of HIV-1-infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine.With the FDA granting a Priority Review in June, a decision is expected on Dec 29, 2019.
Meanwhile, ViiV Healthcare also announced the start of the first-ever study — CUSTOMIZE — to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in the real world. This approach can be different and an improvement from the controlled setting of a clinical study
ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer (PFE - Free Report) .
So far this year, Glaxo’s shares have outperformed the industry, rising 6% compared with the industry’s 2.6% increase.
HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, Tivicay, Triumeqand Juluca in its portfolio. In April, ViiV Healthcare gained FDA approval for a single-tablet two-drug regimen, Dovato for treatment naïve HIV- 1 adults. HIV sales totaled £1.12 billion in the first quarter of 2019 with dolutegravir-based regimens generating £1.07 million, which partly offset lower sales of established HIV products. However, on the call, the company specified that growth in the dolutegravir franchise was slower than past quarters due to a more competitive environment.
ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralizing antibodies). Other than the long-acting, injectable two-drug regimen of cabotegravir and rilpivirine, Glaxo has fostemsavir in its HIV pipeline, which has been developed to treat heavily pre-treated HIV patients. An NDA for fostemsavir is expectedto be filedin second-half 2019.
Other key players in the HIV market are Gilead (GILD - Free Report) , Merck, AbbVie and J&J.
Glaxo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>